| Autor: |
Illerhaus, G., Ferreri, A., Binder, M., Borchmann, P., Hasenkamp, J., Stilgenbauer, S., Roeth, A., Weber, T., Egerer, G., Ernst, T., Hertenstein, B., Lenz, G., Kobbe, G., Brunnberg, U., Schmidt, C., Kneba, M., Dreyling, M., Möhle, R., Panse, J., Heinicke, T. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p41-43, 3p |
| Abstrakt: |
To clarify, whether minimal residual disease may also be eliminated by non-myeloablative IT, comprising non-cross resistant cytotoxic agents, the MATRix/IELSG43 trial, an international randomised phase III trial comparing HDC-ASCT with non-myeloablative consolidation in patients with newly diagnosed PCNSL (NCT02531841) was conducted. B Background b : Current treatment options for patients with primary central nervous system lymphoma (PCNSL) eligible for intensive treatment approaches comprise high-dose methotrexate (HD-MTX) based immuno-chemotherapy (IT) followed by consolidating high-dose chemotherapy and ASCT (HDC-ASCT). CONSOLIDATIVE HCT-ASCT IS SUPERIOR TO NON-MYELOABLATIVE CHEMO-IMMUNOTHERAPY IN NEWLY-DIAGNOSED PCNSL - UPDATED RESULTS OF THE RANDOMIZED PHASE III MATRIX/IELSG43 TRIAL. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text